ACADIA Pharmaceuticals is projected to report Q3 2026 revenue of $268.4 million and an EPS of $0.19, with the current stock price of $18.62 trading significantly below the $26.45 average analyst target. The primary focus for investors this quarter is the commercial trajectory and patient retention rates for Daybue (trofinetide) in the Rett syndrome market.
While Nuplazid remains a foundational cash generator in Parkinson's disease psychosis, Daybue is the company's primary growth engine and critical to its valuation. Analysts are specifically looking for evidence of stabilized refill rates and progress on international expansion plans for the Rett syndrome franchise.